{"id":731851,"date":"2023-02-15T16:16:49","date_gmt":"2023-02-15T21:16:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/"},"modified":"2023-02-15T16:16:49","modified_gmt":"2023-02-15T21:16:49","slug":"atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/","title":{"rendered":"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Feb.  15, 2023  (GLOBE NEWSWIRE) &#8212; Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (\u201cAtea\u201d), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February 19-22, 2023 in Seattle, Washington.<\/p>\n<p>Details for the poster presentations are as follows:<\/p>\n<p>\n        <strong>Poster Number: <\/strong>512\u00a0<br \/><strong>Title:<\/strong> No Dose Adjustments for CYP3A4 Substrates When Co-Administered with Bemnifosbuvir<br \/><strong>Session:\u00a0<\/strong>Pharmacokinetics\/Pharmacodynamics of SARS-CoV-2 Therapeutics<\/p>\n<p><strong>Poster Number: <\/strong>513\u00a0<br \/><strong>Title: <\/strong>Bemnifosbuvir Has Low Potential to Inhibit P-gp, BCRP, and OATP1B1 Mediated Transport<br \/><strong>Session:\u00a0<\/strong>Pharmacokinetics\/Pharmacodynamics of SARS-CoV-2 Therapeutics<\/p>\n<p><strong>About Atea Pharmaceuticals<\/strong><\/p>\n<p>Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with severe viral diseases. Leveraging the Company\u2019s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Currently, Atea is focused on the clinical development of orally-available antiviral agents for difficult-to-treat, severe viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus and hepatitis C virus (HCV). For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m9-QibJqQyfnP1tel9Kf0_heHQDhKUp7cZ-VowSXqEYuBXV8fkphgibgn6mmtdo1oEV2ZWexIrg7RuGvArGtxDJdWLY2ZoHx-sICaVP3Jo5e5-zCuSvTg8c37fxpkkdoqbDmi5GLLOCz8F4ohoxagWnlYVAu_OOB7Sd7m_TyD8Vz8h6oC8T7_6gx5IjIgEootvpYG4oqO8JIXHuoTnWiQvPaZ8C0_bdCcDOKtZTVxmvHSJuJEuTGPJsmXvDqEw2vDxiQtDHV7uSqpaKl3AS6RZD3kSwytCQB9Z2L5URM_HMMr8M07tF9uh_VEw8opODAdC1F2tcD77zrqwO2yg2F1UyT6YfKihJouRTdTc9XwXSMfUTF1oFQc1LPIawG0h2ftY5rtphdVS6M4e3MPSRqA9AdiqqqjyMaursuLbdDoa4Xo6p2Oz7rP6nEyAwWBq12ErJ5UB5VZ7gk4Eu24o4NeQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.ateapharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our product candidates, including bemnifosbuvir combination product candidates, and expectations regarding our pipeline, including trial design and development timelines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the uncertainty around and costs associated with the clinical development of bemnifosbuvir as a potential treatment for COVID-19, bemnifosbuvir and ruzasvir for the potential treatment of HCV and AT-752 for dengue. These and other important factors discussed under the caption \u201cRisk Factors\u201d in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management\u2019s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>Jonae Barnes<br \/>SVP, Investor Relations and Corporate Communications<br \/>617-818-2985<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gUHJCjp56GKRL5ddFYWuP0h_t4YhEPXejxbvLLHf11wfpMV9PhMbl7HVZZyNqWWm3EbdVrtwRfk5srhI2S455L66hB-xxbQdTa7V6Yo3ERVVIyeJy_tmrUS21tqza_bu\" rel=\"nofollow noopener\" target=\"_blank\">Barnes.jonae@ateapharma.com<\/a><\/p>\n<p>Will O\u2019Connor<br \/>Stern Investor Relations <br \/>212-362-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wKV4OusabHVGdDPYkT31DHQdeCBFK34JqOk6HRaY9Aaivwj4wpt3POmq9q38k28NwQkn4I5T7f-Hb-pnmkOfdp59zsGyEBfgqbv5EO0b6FA=\" rel=\"nofollow noopener\" target=\"_blank\">will.oconnor@sternir.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWM0NjI3ZWUtODU4MS00ZjQyLThmN2YtMmMyNjQyNjM4ZmNiLTEyMDkwMzQ=\/tiny\/Atea-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) &#8212; Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (\u201cAtea\u201d), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February 19-22, 2023 in Seattle, Washington. Details for the poster presentations are as follows: Poster Number: 512\u00a0Title: No Dose Adjustments for CYP3A4 Substrates When Co-Administered with BemnifosbuvirSession:\u00a0Pharmacokinetics\/Pharmacodynamics of SARS-CoV-2 Therapeutics Poster Number: 513\u00a0Title: Bemnifosbuvir Has Low Potential to Inhibit P-gp, BCRP, and OATP1B1 Mediated TransportSession:\u00a0Pharmacokinetics\/Pharmacodynamics of SARS-CoV-2 Therapeutics About Atea Pharmaceuticals Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with severe viral diseases. Leveraging the Company\u2019s deep understanding of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-731851","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) &#8212; Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (\u201cAtea\u201d), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February 19-22, 2023 in Seattle, Washington. Details for the poster presentations are as follows: Poster Number: 512\u00a0Title: No Dose Adjustments for CYP3A4 Substrates When Co-Administered with BemnifosbuvirSession:\u00a0Pharmacokinetics\/Pharmacodynamics of SARS-CoV-2 Therapeutics Poster Number: 513\u00a0Title: Bemnifosbuvir Has Low Potential to Inhibit P-gp, BCRP, and OATP1B1 Mediated TransportSession:\u00a0Pharmacokinetics\/Pharmacodynamics of SARS-CoV-2 Therapeutics About Atea Pharmaceuticals Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with severe viral diseases. Leveraging the Company\u2019s deep understanding of &hellip; Continue reading &quot;Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-15T21:16:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections\",\"datePublished\":\"2023-02-15T21:16:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/\"},\"wordCount\":540,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/\",\"name\":\"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE=\",\"datePublished\":\"2023-02-15T21:16:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/","og_locale":"en_US","og_type":"article","og_title":"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections - Market Newsdesk","og_description":"BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) &#8212; Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (\u201cAtea\u201d), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February 19-22, 2023 in Seattle, Washington. Details for the poster presentations are as follows: Poster Number: 512\u00a0Title: No Dose Adjustments for CYP3A4 Substrates When Co-Administered with BemnifosbuvirSession:\u00a0Pharmacokinetics\/Pharmacodynamics of SARS-CoV-2 Therapeutics Poster Number: 513\u00a0Title: Bemnifosbuvir Has Low Potential to Inhibit P-gp, BCRP, and OATP1B1 Mediated TransportSession:\u00a0Pharmacokinetics\/Pharmacodynamics of SARS-CoV-2 Therapeutics About Atea Pharmaceuticals Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with severe viral diseases. Leveraging the Company\u2019s deep understanding of &hellip; Continue reading \"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-15T21:16:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections","datePublished":"2023-02-15T21:16:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/"},"wordCount":540,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/","name":"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE=","datePublished":"2023-02-15T21:16:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MDA5OCM1NDExNzQ4IzIxOTc0ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-data-on-bemnifosbuvir-drug-interaction-profile-at-conference-on-retroviruses-and-opportunistic-infections\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/731851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=731851"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/731851\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=731851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=731851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=731851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}